Skip to content

Study · Animal study (in vivo) · rat · 1994

3 results

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats.

Ugwu SO, Blanchard J, Nguyen LD, Hadley ME, Dorr RT

Biopharmaceutics & drug disposition1 Jul 1994Cited by 9 (Europe PMC)

PMID7981427 (opens in a new tab)DOI10.1002/bdd.2510150505 (opens in a new tab)PepBankPUB-07981427
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats given MT-II intravenously, plasma concentration versus time plots showed biphasic disposition profiles.

    In plain wordsIn rats given MT-II into a vein, blood levels fell in two phases over time.

    Peptide
    Melanotan II
    Outcome
    Not applicablePlasma concentration-time profile
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.3 mg/kg · intravenousAs given in this study (rat).

    Measurements

    dose
    0.3 mg/kg
    intravenous

    Source sentences

    Summary
    The pharmacokinetic profile of the melanotropic peptide, melanotan-II (MT-II), was determined in rats following a 0.3 mg kg-1 intravenous dose.
    1 context sentence
    Summary · context
    The plasma concentration versus time plots determined using the two assay methods yielded biphasic disposition profiles that were essentially superimposable.

Studies that did not test the peptide alone2

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Other

    In rat plasma, MT-II concentrations measured by HPLC and by bioassay showed a significant linear correlation.

    In plain wordsIn rat blood samples, two lab methods for measuring MT-II gave closely matching results.

    Peptide
    Melanotan II
    Outcome
    Not applicableCorrelation of HPLC and bioassay plasma MT-II concentrations
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    correlation coefficient
    0.9 r
    HPLC versus bioassay

    Source sentences

    Summary
    Regression analysis of the plasma MT-II concentrations determined using HPLC and bioassay methods indicated the existence of a significant linear correlation (r = 0.90, p < 0.001).

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Other

    In rat plasma, pharmacokinetic parameters from the two assay methods did not differ significantly, except t1/2 beta, MRT and Vss.

    In plain wordsIn rat blood samples, two lab methods gave similar MT-II measures, except for three parameters that differed.

    Peptide
    Melanotan II
    Outcome
    MixedAgreement of pharmacokinetic parameters between assay methods
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Statistical comparison showed that the parameters measured by each method were not significantly different (at the 0.05 level) except for t1/2 beta, MRT and Vss.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.